The Cannabis Industry Quarterly Update: Q3 2023 reports that the U.S. Department of Health and Human Services (HHS) has suggested a significant amendment to the U.S. Drug Enforcement Agency’s (DEA) classification of cannabis. HHS recommended the reclassification of cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA). This recommendation arrived ten months following a call from the Biden Administration for a review of the federal legal scheduling of cannabis. The review was directed at both the Secretary of HHS and the Attorney General.
This move, if executed, would mark a substantial change in the way cannabis is regulated on a federal level. The current Schedule I categorization connotes that cannabis has a high tendency for potential abuse and lacks accepted medical use, an assertion that is increasingly being challenged both scientifically and in public perception.
The reclassification to Schedule III would align cannabis with substances such as codeine, anabolic steroids and ketamine, which are substances considered to have a moderate to low potential for physical and psychological dependence.
The implications of such a change are vast. Shifting cannabis to Schedule III would potentially ease restrictions on cannabis research and development, expanding the understanding of medical usage and potential benefits. Additionally, it may lead to broader changes in how the legal and business landscapes around cannabis are navigated, opening up new markets and opportunities for legal professionals working within and alongside the growing cannabis industry.